PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.
Valeant gave $100,000 to patient group to address affordability of its drug; Omnicom reports 3% increase in specialty group revenue; Verily to study biometric data
The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
The drugmaker hopes its emojis will raise awareness about treatment options for constipation.
Along with lower costs, effective co-pay offset programs boost patient adherence and better connect with doctors and pharmacies.
Kardashian West promotes Diclegis again; drugmakers are developing non-opioid painkillers; healthcare brands test Facebook Live
This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
The drugmaker saw a gap in patient-physician conversation about retinal disease.
Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug
A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.
Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments
Meet Medela's Katie Busse, Intouch Solutions' Andrew Grojean, Heartbeat's Meghan Kate, Fingerpaint's Travis Rooke, and Havas Life Metro's Dan Sorine.
The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test
Bayer, Eli Lilly, GlaxoSmithKline, and Sanofi have suspended advertising on the show, according to news reports.
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
Several of the top-spending brands have never hired more than one female or non-white marketing boss, and some never have.
GSK pulls ads from "The O'Reilly Factor"; the FDA approves drug for Huntington's disease patients; lawmakers may remove pre-existing conditions requirement
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Tom Noland says protecting and enhancing Humana's reputation comes down to three things: corporate volunteerism, good media relations, and content creation.
A WebMD survey finds that patients are more engaged when they share their own health with their doctors.
Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics
This year's festival will be held June 17 and 18.
Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law
Agency vets Nadine Leonard and James Talerico to co-lead Publicis-owned shop.
A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year
The committee is seeking information about the companies' sales and marketing strategies.
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Drugmakers again spent more on DTC advertising in 2016 than the year before.
Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?
Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results
Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.
Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker
P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche
Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.
Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.
Seven execs from A-list agencies weigh in on talent acquisition and retention.
The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised
Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.
Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices
PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.
Allergan's national vision-loss-prevention campaign, See America, has brought on rapper Common as a celebrity spokesman.
The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits
Organizations are focusing on better ways to verify HCPs' digital identities.
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
SXSW's health track finally got a seat at the big-kids table.
Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.
The MM&M Transforming Healthcare Conference will be held May 1 in New York City.
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
The organization is now called Havas Health & You and continues to be led by Donna Murphy.
Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled
He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.
The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies
About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.
The new spot for its cholesterol-lowering injection debuted last week.
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
Pfizer and Bristol-Myers Squibb were the top spenders last year.
Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
He describes his current charge as "transforming a more creative occupation into a science."
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Valeant added 250 primary care sales reps to promote its Salix portfolio.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Drugmakers battle for slice of Humira's billions
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- Five things for pharma marketers to know: Thursday, April 27, 2017
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.